TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
Biotec Betaglucans AS
Closing information (x1000 EUR)
| Closing information | 2025/01 | 2024/01 | 2023/01 |
| Turnover |
3,897
|
2,846
|
1,496 |
| Financial expenses |
115
|
157
|
199 |
| Earnings before taxes |
656
|
301
|
218 |
| Total assets |
2,901
|
2,928
|
2,089 |
| Current assets |
1,663
|
2,226
|
1,815 |
| Current liabilities |
1,394
|
1,696
|
835 |
| Equity capital |
1,506
|
1,232
|
1,254 |
| - share capital |
85
|
88
|
92 |
Financial ratios
| Fiscal year | 2025/01 | 2024/01 | 2023/01 |
| Solvency |
51.9%
|
42.1%
|
60.0% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
16.8%
|
10.6%
|
14.6% |
| Return on assets (ROA) |
26.6%
|
15.6%
|
20.0% |
| Current ratio |
119.3%
|
131.2%
|
217.4% |
| Return on equity (ROE) |
43.6%
|
24.4%
|
17.4% |
| Change turnover |
1,144
|
1,420
|
-897 |
| Change turnover % |
42%
|
100%
|
-37% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2025/01 | 2024/01 | 2023/01 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.